I have often had men recently diagnosed with advanced, metastatic prostate cancer call me and ask if surgery makes any sense for them to consider. I have never been sure how to respond given that their cancer is known to be already out of their gland. In response to this common question, researchers from the [...]
Cancer is a genetic disease, so prostate cancer is a genetic problem. This statement might be the most important one we can make when trying to describe the current, overall situation we face as prostate cancer survivors! Many institutions have begun significant research studies trying to understand the actual genetic keys to prostate cancer. Prostate [...]
Understanding a little about the prostate gland and its biology is not only interesting, but it allows us to ask some important questions that can positively inform our treatment decisions and eventually the outcomes. On the other hand, it also can add to the confusion we all face in making the best clinical decisions. Like [...]
Clinical trials have shown that there is an overall survival and radiographic progression-free survival benefit derived from abiraterone acetate (Zytiga) in the treatment of men with metastatic castration resistant prostate cancer (mCRPC). A new retrospective study published online, ahead of print, shows this trend is true regardless of a man's Gleason score at diagnosis, despite [...]
Knowing the negative prognostic factors for successful treatment when you have a a biochemical recurrence (PSA only) of your prostate cancer is important. These factors can help you make your treatment decisions because they assist you in evaluating your possible clinical outcome. In a single institutional review of negative prognostic outcomes of salvage radiotherapy in [...]